- Home
- OGN vs VCEL Comparison
OGN vs VCEL Comparison
Compare OGN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGN
- VCEL
- Stock Information
- Founded
- OGN 1923
- VCEL 1989
- Country
- OGN United States
- VCEL United States
- Employees
- OGN N/A
- VCEL N/A
- Industry
- OGN Biotechnology: Pharmaceutical Preparations
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGN Health Care
- VCEL Health Care
- Exchange
- OGN Nasdaq
- VCEL Nasdaq
- Market Cap
- OGN 2.5B
- VCEL 2.1B
- IPO Year
- OGN N/A
- VCEL 1997
- Fundamental
- Price
- OGN $9.76
- VCEL $42.29
- Analyst Decision
- OGN Hold
- VCEL Strong Buy
- Analyst Count
- OGN 4
- VCEL 8
- Target Price
- OGN $18.00
- VCEL $62.00
- AVG Volume (30 Days)
- OGN 4.6M
- VCEL 431.2K
- Earning Date
- OGN 08-05-2025
- VCEL 07-31-2025
- Dividend Yield
- OGN 8.77%
- VCEL N/A
- EPS Growth
- OGN N/A
- VCEL 521.85
- EPS
- OGN 2.88
- VCEL 0.05
- Revenue
- OGN $6,294,000,000.00
- VCEL $238,541,000.00
- Revenue This Year
- OGN N/A
- VCEL $23.03
- Revenue Next Year
- OGN $1.11
- VCEL $24.52
- P/E Ratio
- OGN $3.41
- VCEL $818.49
- Revenue Growth
- OGN N/A
- VCEL 14.80
- 52 Week Low
- OGN $8.01
- VCEL $37.39
- 52 Week High
- OGN $23.10
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- OGN 49.46
- VCEL 49.21
- Support Level
- OGN $9.88
- VCEL $40.41
- Resistance Level
- OGN $10.30
- VCEL $42.49
- Average True Range (ATR)
- OGN 0.38
- VCEL 1.67
- MACD
- OGN 0.11
- VCEL -0.15
- Stochastic Oscillator
- OGN 60.66
- VCEL 43.76
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.